Clinical efficacy of riboflavin and ultraviolet light inactivated fresh frozen plasma evaluated with INR-quantification

Transfusion and Apheresis Science

Volumn 47, Issue 1, 2012, Pages 33-37

  Stanojkovic, Zoran ^a,b   Balint, Bela ^c,d   Antic, Ana ^a   Todorovic, Milena ^e,f   Ostojic, Gordana ^d   Pavlovic, Mirjana ^g  

^a Blood Transfusion Institute   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF DEFENCE   (Serbia)

^e CLINICAL CENTER OF SERBIA   (Serbia)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g Florida Atlantic University   (United States)

Author keywords

Inactivation; INR; Plasma; Riboflavin; Ultraviolet light

Indexed keywords

FRESH FROZEN PLASMA; RIBOFLAVIN;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD TRANSFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; ULTRAVIOLET RADIATION;

ADULT; BLOOD COAGULATION DISORDERS; BLOOD COMPONENT TRANSFUSION; DISINFECTION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 84862880209     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2012.03.006     Document Type: Article

References (20)

1. McCullough J. Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections. Am J Clin Pathol 2007, 128:945-955.
2. Klein H.G., Bryant B.J. Pathogen-reduction methods: advantages and limits. Vox Sang 2009, 4:154-160.
3. Klein H.G., Anderson D., Bernardi M.J., Cable R., Carey W., Hoch J.S., et al. Pathogen inactivation: making decisions about new technologies. Transfusion 2007, 47:2338-2347.
4. Petteys B.J., Frank E.L. Rapid determination of vitamin B2 (riboflavin) in plasma by HPLC. Clin Chim Acta 2011, 14(412):38-43.
5. Goodrich R.P., Doane S., Reddy H.L. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010, 38:20-30.
6. Goodrich R.P., Li J., Edrich R., Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006, 35:5-17.
7. Reddy H.L., Dayan A.D., Cavagnaro J., Gad S., Li J., Goodrich R.P. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008, 22:133-153.
8. Janetzko K., Hinz K., Marschner S., Goodrich R., Kluter H. Pathogen reduction technology (Mirasol®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang 2009, 97:234-239.
9. Bihm D.J., Ettinger A., Buytaert-Hoefen K.A., Hendrix B.K., Maldonado-Codina G., Rock G., et al. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30°C. Vox Sang 2010, 98:108-115.
10. Stanojkovic Z., Antic A., Stojanovic M. Effectiveness of riboflavin and ultraviolet light based pathogen inactivation on quality of platelet concentrates. Vojnosanit Pregl 2011, 68:489-494.
11. Jocic M., Trkuljic M., Jovicic D., Borovcanin N., Balint B. Mirasol PRT inactivation efficacy in platelet concentrates determined by a bacteria-contamination model. Vojnosanit Pregl 2011, 68:1041-1046.
12. Antic A., Stanojkovic Z., Macukanovic-Golubovic L., Jelic M. Evaluation of coagulation factors in fresh frozen plasma treated with riboflavin and ultraviolet light. Vojnosanit Pregl 2012, 69:22-26.
13. Balint B., Taseski J. Therapeutic use of blood products and their recombinant analogs in patients with disorders of hemostasis. Vojnosanit Pregl 2000, 57(5 Suppl.):69-80.
14. Hornsey V.S., Drummond O., Morrison A., McMillan L., Macgregor I.R., Prowse C.V. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009, 49:2167-2172.
15. Larrea L., Calabuig M., Roldan V., Rivera J., Tsai H.M., Vicente V., et al. The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 2009, 4:199-204.
16. Smith J.W. Protein quality in Mirasol pathogen reduction technology treated apheresis derived FFP. Transfusion 2008, 48(Suppl. s2):146A.
17. Bihm D. Protein quality of previously frozen plasma treated with the Mirasol pathogen inactivation process and stored for two years. Vox Sang 2009, 96:375-380.
18. Buytaert-Hoefen K., Gampp D., Edrich R., Hendrix B., Goodrich R. Mirasol pathogen treated plasma maintains protein quality. Transfusion 2007, 47(Suppl. s3):74A.
19. Holand L.L., Brooks J.P. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006, 126:133-139.
20. Shinagare S.A., Angarkar N.N., Deasi R.R., Naniwadekar M.R. An audit of fresh frozen plasma usage and effect of fresh frozen plasma on the pre-transfusion international normalized ratio. Asian J Transf Sci 2010, 4:127-132.